Trastuzumab emtansine | 曲妥珠单抗-美坦新偶联物

中文名：曲妥珠单抗-美坦新偶联物

CAS：1018448-65-1

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：曲妥珠单抗 emtansine (Ado-Trastuzumab emtansine) 是一种抗体药物偶联物 (ADC)，它结合了曲妥珠单抗的 HER2 靶向抗肿瘤特性和微管抑制剂 DM1（美登素的衍生物）的细胞毒活性. Trastuzumab emtansine可用于晚期乳腺癌的研究^[1][2]。

^{体外：Trastuzumab emtansine (2 μg/mL; 3 d) 显着抑制上皮性卵巢癌 (EOC) 细胞的增殖[2]。}

体内：Trastuzumab emtansine（15 mg/kg；每周静脉注射 3 至 5 次，持续 3 周）在小鼠体内表现出显着的抗肿瘤作用^[2]。

参考文献：

[1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.

[2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.